Background {#Sec1}
==========

Five hundred thousand patients in the United States receive maintenance hemodialysis (MHD) for end-stage renal disease (ESRD) \[[@CR1]\]. Life expectancies for MHD patients are 17--34 % less than those of the general population \[[@CR2]\]. Some of this excess mortality may be attributable to an increased risk of cardiovascular disease as a result of increased oxidative stress \[[@CR3], [@CR4]\]. Oxidative stress can originate from multiple sources, including the decoupling of the electron transport chain in the mitochondria and inflammation-mediated production of superoxide via NADPH-oxidase and resulting altered oxygen handling capacity.

Coenzyme Q~10~ (CoQ~10~) is a required component of the mitochondrial electron transport chain, where it transfers electrons from complexes 1 and 2 to complex 3. Reduction and oxidation of CoQ~10~ also reduces lipid radicals and oxidizes superoxide. CoQ~10~ depletion leads to inefficient electron transport, increased reactive oxygen species (ROS) production, decreased adenosine triphosphate (ATP) production, and altered mitochondrial membrane potential \[[@CR5]\]. CoQ~10~ treatment, on the other hand, improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure \[[@CR6]\]. In addition to the effects on mitochondrial transport, CoQ~10~ also exerts global antioxidant effects, with the reduced form able to react directly with free radicals, wherein it is converted to the oxidized form \[[@CR7]\]. For these reasons, CoQ~10~ is frequently administered as a dietary supplement in alternative and complementary therapy, but no studies have examined high dose CoQ~10~ tolerability and efficacy in dialysis patients, a population with increased oxidative stress \[[@CR8], [@CR9]\]. F~2~-isoprostane and isofuran concentrations, products of non-enzymatic arachidonic acid peroxidation, are considered one of the most reliable approaches for assessing systemic oxidative stress in vivo \[[@CR10]\]. The formation of F~2~-isoprostanes and isofurans is differentially regulated by oxygen tension; the formation of F~2~-isoprostanes is favored at low oxygen tensions whereas the formation of isofurans is favored at high oxygen tensions, as occurs in the setting of mitochondrial dysfunction \[[@CR11], [@CR12]\]. Plasma F~2~-isoprostane concentrations have been shown to be two to four times higher in dialysis patients than in age- and gender- matched healthy subjects \[[@CR13], [@CR14]\], consistent with the increased oxidative burden in this population. Plasma isofuran concentrations have not previously been reported in dialysis patients.

The present study tested the hypothesis that oral CoQ~10~ administration is safe, well-tolerated, and decreases oxidative stress in MHD patients, with the additional goals of determining the maximum well-tolerated dose of CoQ~10~.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

We performed an open label, dose-escalation study (Fig. [1](#Fig1){ref-type="fig"}) to evaluate the safety and tolerability of CoQ~10~ in HD patients using a commercially available CoQ~10~ chewable wafer (Vitaline Formulas, Wilsonville, OR).Fig. 1CoQ~10~ dose escalation study design. \*Measurement of plasma CoQ10, comprehensive metabolic panel, creatine phosphokinase, and oxidative stress biomarkers

Study population {#Sec4}
----------------

End stage renal disease patients, between the ages of 18 and 85 years, receiving thrice weekly dialysis using high-flux dialyzers, with a life expectancy of \>1 year, and a baseline plasma F~2~-isoprostane concentration greater than or equal to 50 pg/ml were eligible for study. Twenty MHD subjects were enrolled from two university medical centers. All subjects provided written informed consent that was approved by the University of Washington and the Vanderbilt University Institutional Review Boards. All study procedures were conducted in accordance with Helsinki Declaration of 1975 (as revised in 2000).

Subject exclusion criteria included: history of poor adherence to MHD or medical regimen, AIDS (HIV seropositivity was not an exclusion criteria), active malignancy excluding basal cell carcinoma of the skin, gastrointestinal dysfunction requiring parenteral nutrition, kidney transplant \< 6 months prior to study entry or anticipated live donor kidney transplant, current use of vitamin E supplements \> 60 IU/day, vitamin C supplements \> 150 mg/day, current use of l-carnitine or other antioxidant or nutritional supplements, initiation of hemodialysis within 90 days prior to study enrollment, hospitalization within the past 60 days, dialysis with a tunneled catheter as a temporary vascular access, and a history of a major atherosclerotic event (defined as myocardial infarction, urgent target-vessel revascularization, coronary artery bypass surgery, or stroke) within six months.

Plasma samples from healthy control subjects (*n* = 10) were randomly selected from the Kidney Research Institute biorepository. Healthy control subjects had normal kidney function and were not taking statin medications. Healthy control subjects were not matched for age, race, or gender with subjects receiving CoQ~10~ supplementation. The control subjects were younger, more likely to be female, and less likely to be taking a statin than the dialysis subjects.

With a sample size of 20 subjects, we predicted that we would have at least 94 % power to detect a 45 % change in plasma F~2~-isoprostane levels after CoQ~10~ administration (estimated mean plasma F~2~-isoprostane concentrations in MHD patients = 96 pg/mL, with a standard deviation of 49 pg/mL), assuming a 2-sided, 0.05 alpha level using a paired *t*-test approach.

CoQ~10~ dose escalation {#Sec5}
-----------------------

Subjects were administered 300 mg CoQ~10~ for 14 days and then 600, 1200, and 1800 mg CoQ~10~ daily, each for 14 days. Subjects returned to the clinic at the end of each dosing period and spontaneously reported adverse events were recorded at every visit. Blood samples were collected at baseline, and after each 14-day course of treatment for determination of comprehensive metabolic panel (electrolytes, blood urea nitrogen, creatinine, glucose, albumin, total protein, calcium, alkaline phosphatase, ALT, AST, total bilirubin), creatine phosphokinase (CPK), F~2~-isoprostane and isofuran concentrations. Blood samples for High Density Lipoprotein (HDL) apoA-1 Met(O) were collected at baseline and following 1200 mg dosing period. All blood samples were immediately chilled, and then centrifuged within one hour of collection at 2500 RPM, 4 °C, for 15 min. Plasma (heparinized) was removed and stored at −80 °C until analysis. Ten subjects participated in an additional study in which CoQ~10~ levels were measured prior to and immediately following standard HD to assess the effect of HD on plasma CoQ~10~ concentrations. CoQ~10~ concentrations were also measured in the plasma of the 10 unmatched healthy control subjects. Access to the remaining samples may be granted by contacting the corresponding author.

Assays {#Sec6}
------

For CoQ~10~ measurement, plasma samples were thawed on ice, and a 100 μl aliquot was mixed with 200 μL ice cold 1-propanol containing Coenzyme Q~9~ (CoQ~9~) and CoQ~9~H~2~ as internal standards. Precipitated proteins were removed by cold centrifugation, and the supernatant injected directly onto the LC-MS/MS for analysis. Samples in the autosampler were held at 4 °C until injection. Chromatography of the analytes was accomplished using an Agilent 1200s-series LC system equipped with a Zorbax SB-C~18~ column (30 mm × 2.1 mm × 3.5 μM particle size) that was maintained at 40 °C. The mobile phase consisted of a binary gradient of methanol and 5 mM ammonium formate pumped at a flow rate of 0.8 mL/min. The MS/MS was operated in positive ESI mode with nitrogen as drying gas at a flow of 10 L/min and 350 °C, and with nitrogen nebulizer gas set at 35 psi. The monitored transitions for CoQ~10~H~2~, CoQ~10~, CoQ~9~H~2~ and CoQ~9~ were *882.7 → 197.1, 863.7 → 197.1, 814.7 → 197.1,* and *795.6 → 197.1* respectively. Method validation, including stability of analytes and internal standards, and comparisons to established methods are detailed in reference \[[@CR15]\].

For F~2~-isoprostane and isofuran measurements, internal standard \[^2^H~4~\]-15-F~2T~-isoprostane was added to each plasma sample prior to C-18 and silica solid phase extraction, thin layer chromatography, and derivatization to penta-fluorobenzyl ester, trimethylsilyl ether derivative \[[@CR16]\]. GC/NICI-MS was performed (Agilent 5973) using 15 m x 0.25 μm thick fused silica capillary columns (J and W Scientific). The major ion generated was m/z 569 carboxylate anion \[M-181 (M-CH~2~C~6~F~5~)\]. The corresponding ion generated from the \[^2^H~4~\]-15-F~2T~-isoprostane internal standard was m/z 573, and the isofuran ion was *m/z* 585.

For Met(O) measurement, HDL was isolated, digested and oxidation of Met residues in apoA-I of HDL was quantified by isotope dilution mass spectrometry (MS) and selective reaction monitoring (SRM) on a Thermo TSQ Vantage coupled to a Waters nanoACQUITY UltraPerformance liquid chromatography system as previously described \[[@CR17]\].

Comprehensive metabolic panel and CPK measurements were performed in the CLIA-certified hospital laboratories of University of Washington Medical Center and Vanderbilt University Medical Center. Plasma IL-6 was measured using a commercial kit according to the manufacturer's protocol (R&D Systems, Minneapolis MN).

Data analysis {#Sec7}
-------------

Mean baseline values and change from baseline were determined for CoQ~10~ concentrations, all safety endpoints (comprehensive metabolic panel, CPK, electrocardiogram results, physical examination findings), and efficacy measures (oxidative stress biomarker concentrations). Each of these parameters was analyzed via one-way repeated measures analysis of variance to determine the presence or absence of dose-related differences. In addition, mixed effects modeling was used to test the effect of increased CoQ~10~ dose and duration with fixed effect of time (dose), random subject effect, and an unstructured repeated covariance type. Study subject concentrations of CoQ~10~, F~2~-isoprostanes, and isofurans were also compared to concentrations in non-dialysis historical control subjects. The primary analysis included all subjects. Subgroup analyses were conducted in statin treated (*n* = 6) and non-statin treated (*n* = 14) subjects. Spearman's correlation coefficients were used to assess correlations between plasma CoQ~10~ concentrations and oxidative stress biomarkers. Two-tailed *P*-values ≤ 0.05 were considered significant in all analyses. When appropriate, corrections were made for multiple comparisons. Statistical analysis was conducted using STATA 11.0 and SAS 9.1 (SAS Institute, Cary, NC, USA). Data is expressed as mean ± standard deviation unless otherwise specified.

Results {#Sec8}
=======

Twenty subjects were recruited for the study, fifteen of whom completed the entire dose escalation protocol (Fig. [2](#Fig2){ref-type="fig"}). The mean age of subjects was 58 years with 8 females studied. Average length of time on dialysis was 8.0 ± 8.9 years (range 0.7 to 29.4 years). Seven subjects were taking statin medications. Three subjects discontinued study participation due to abdominal pain or nausea; one during the 300 mg/day period, one during the 1200 mg/day period, and one after the 1800 mg/day period. One subject discontinued participation after an unrelated elevation in INR (international normalized ratio), and one subject discontinued participation after damaging a tooth from chewing the CoQ~10~ wafer. Three subjects reported stomach discomfort at the 1800 mg/day dose but completed the study. One subject was found expired at home 22 days after completing the study. This death was attributed to natural causes and was deemed to be unrelated to study participation.Fig. 2Overview of study subject participation and study withdrawal

Plasma CoQ~10~ concentrations {#Sec9}
-----------------------------

Mean plasma total CoQ~10~ levels at baseline (prior to a mid-week dialysis session) were 704 ± 286 ng/mL, significantly lower than CoQ~10~ levels in healthy control patients (1385 ± 640 ng/mL, *P* = 0.0014). Plasma CoQ~10~ concentrations increased linearly with escalation of CoQ~10~ dose (Fig. [3](#Fig3){ref-type="fig"}). At the end of the 1800 mg/day dosing period, total CoQ~10~ plasma concentrations averaged 4032 ± 1637 ng/mL (*P* \< 0.001 compared to baseline and to healthy controls). The CoQ~10~ redox ratio (CoQ~10~H~2~:CoQ~10~) increased from 14 ± 7.4 at baseline to 22 ± 9 after supplementation (*P* = 0.013). Despite this increase, the redox ratio remained significantly less than that observed in healthy controls (41 ± 12, *P* \< 0.001, Fig. [3](#Fig3){ref-type="fig"}). Statin using (*n* = 6) and non-using (*n* = 14) subjects had similar plasma concentrations of CoQ~10~ and CoQ~10~H~2~: CoQ~10~ ratios at baseline and at the end of the study (3438 ± 1899 ng/mL, redox ratio 25.7 ± 9.4 in statin users vs. 4080 ± 1467 ng/ml, redox ratio 18.8 ± 6.5 in statin non-users at the end of the study; *P* = 0.31 for CoQ~10~ plasma concentration, *P* = 0.10 for redox ratio). Plasma CoQ~10~ levels measured just before and immediately after hemodialysis did not differ significantly (Fig. [4](#Fig4){ref-type="fig"}), indicating that hemodialysis does not clear the lipophilic CoQ~10~ from blood or acutely alter the circulating pool of CoQ~10~ (*p* = 0.72).Fig. 3Effect of Coenzyme Q~10~ supplementation on plasma concentrations of total CoQ~10~ (**a**) and CoQ~10~(H~2~):CoQ10 ratios (**b**) (mean ± SD) in study subjects and unmatched healthy controls. Sample numbers for baseline (0 mg), 300 mg, 600 mg, 1200 mg, 1800 mg, and healthy controls were 20, 19, 19, 18, 15, and 10, respectivelyFig. 4Effect of hemodialysis (HD) on plasma concentrations of CoQ~10~ in study subjects administered 1800 mg of CoQ~10~ for 14 days (*n* = 10). Dark bars indicate total CoQ~10~ levels prior to standard hemodialysis treatment, lighter bars are following hemodialysis. Error bars indicate SD of the means (paired *T*-test for means *p* = 0.72)

Effects of CoQ~10~ supplementation on F~2~-isoprostanes and Isofurans {#Sec10}
---------------------------------------------------------------------

Baseline F~2~-isoprostane and isofuran levels were 66.9 ± 24.9 pg/ml and 141 ± 67.5 pg/ml respectively, notably higher than levels observed in 140 historic control patients not on dialysis (42.5 ± 32.6 pg/mL F~2~-isoprostanes, *P* = 0.002 and 57.0 ± 52.9 pg/mL isofurans, *P* \< 0.001) \[[@CR18]\]. During CoQ~10~ dose escalation, F~2~-isoprostane concentrations did not change compared to baseline (*P* = 0.92). Plasma isofuran concentrations, however, decreased following the 1200 mg (112.8 ± 72.9 pg/ml) and 1800 mg (72.8 ± 37.5 pg/ml) dosing periods (*P* \< 0.001, effect of dose escalation on isofurans, Fig. [5a-c](#Fig5){ref-type="fig"}). Isofuran concentrations following 1800 mg/day CoQ~10~ dosing were 45.1 ± 8.1 % lower than baseline concentrations (*P* = 0.003). In addition, the ratio of isofuran concentrations to F~2~-isoprostane concentrations decreased from 2.56 ± 2.26 to 1.07 ± 0.56 during CoQ~10~ dose escalation (*P* = 0.01), a ratio similar to that observed in non-dialysis control subjects (1.53 ± 1.31, *P* =0.16). Consistent with the effect of CoQ~10~ dose escalation on isofuran concentrations and isofuran:F~2~-isoprostane ratios, plasma concentrations of CoQ~10~ were inversely correlated with isofuran concentrations and isofuran:F~2~-isoprostane ratios (CoQ~10~ isofuran correlation coefficient = −0.29, *P* = 0.02; CoQ~10~ isofurans:F~2~-isoprostanes ratio correlation coefficient = −0.28, *P* = 0.02). There was no correlation between plasma concentrations of F~2~-isoprostanes and plasma CoQ~10~ concentrations (*P* = 0.62, Fig. [5d--f](#Fig5){ref-type="fig"}).Fig. 5Effect of CoQ~10~ dose escalation (**a**--**c**) and total CoQ~10~ plasma concentrations (**d**--**f**) on plasma concentrations of F~2~-isoprostanes, isofurans, and isofuran:F~2~-isoprostane ratios

Effects of CoQ~10~ supplementation on interleukin-6 (IL-6) {#Sec11}
----------------------------------------------------------

Baseline mean IL-6 concentration was 11.2 ± 8.1 ng/ml. During CoQ~10~ dose escalation, IL-6 levels did not change significantly (15.7 ± 18.9 ng/mL at 1800 mg CoQ~10~, *P* = 0.56), and no association was observed between IL-6 levels and plasma CoQ~10~ levels (*P* = 0.20) (Fig. [6a and b](#Fig6){ref-type="fig"}).Fig. 6Effect of CoQ~10~ dose escalation (**a**) and total CoQ~10~ plasma concentrations (**b**) on plasma concentrations of interleukin-6

Effects of CoQ~10~ supplementation on apoprotein A-1 (apoA-1) methionine oxidation (Met(O)) {#Sec12}
-------------------------------------------------------------------------------------------

Oxidation of Met residues 86, 112, or148 in apoA-1 was not different following the 1200 mg CoQ~10~ dosing period, as compared to baseline apoA-1 Met oxidation (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Effect of CoQ10 supplementation (following 1200 mg dosing period) on levels of oxidized methionine (mean ± SD) in apolipoprotein A-I of high density lipoprotein (all p-values \> 0.5)

Safety and tolerability {#Sec13}
-----------------------

Six subjects complained of nausea and abdominal pain during the course of the study. One of these subjects made this complaint during the 300 mg dosing period, two following the 1200 mg dosing period, and three following the 1800 mg dosing period. Three of these subjects discontinued CoQ~10~ treatment, but the other three subjects continued taking CoQ~10~ despite reporting nausea and abdominal pain. Gastrointestinal complaints resolved after discontinuation of CoQ~10~. One subject (non-statin user) was found to have a CPK concentration of 2918 U/L following the 600 mg dosing period but was known to participate in competitive athletics and did not report any myalgia. He remained in the study and following the 1200 mg period his CPK level returned to 311 U/L (similar to his baseline concentration). Overall mean CPK concentrations did not change in the study cohort during CoQ~10~ dose escalation. CoQ~10~ dose escalation did not affect blood pressure.

Discussion {#Sec14}
==========

In this dose escalation study we found oral administration of CoQ~10~ to be safe and well-tolerated at doses under 1800 mg/day. Three of the 5 of the adverse events occurred in subjects receiving more than 1200 mg daily, and only 3 of 6 subjects experiencing adverse effects withdrew from the study. Plasma CoQ~10~ levels increased linearly with dose, suggesting that the chewable wafer used in this study has consistent bioavailability. In addition, our data indicated that CoQ~10~ may reduce systemic oxidative stress in MHD patients in a dose-dependent manner.

CoQ~10~ has been studied extensively in healthy populations and patients with cognitive impairment. In these populations, CoQ~10~ has also been well tolerated. MHD patients are subject to elevated inflammation and oxidative stress as a result of ineffective clearance of uremic toxins, especially middle molecules (molecular weight 300--20,000 Da) \[[@CR19]\] that include circulating cytokines. We have previously observed that MHD patients have 63 % higher concentrations of F~2~-isoprostanes than healthy controls \[[@CR9]\], and a reduction in oxidative stress has been associated with better outcomes in MHD patients. A study by Sakata et al. evaluated the efficacy of a low oral dose of CoQ~10~ (100 mg daily) for 6 months in Japanese MHD patients and demonstrated that CoQ~10~ partially suppressed advanced oxidation protein product accumulation \[[@CR20]\]. Singh et al. also demonstrated a benefit of CoQ~10~ in CKD; subjects who received 60 mg of CoQ~10~ three times daily had reduced serum creatinine and urea concentrations, increased creatinine clearance, and urine output compared with controls \[[@CR21]\]. The doses used in Sakata and Singh studies were lower than those typically used in other studies (300--1200 mg daily); higher doses of CoQ~10~ may be required to substantively reduce oxidative stress in the MHD population. The present study is the first study to evaluate the safety and tolerability of high dose CoQ~10~ in a population receiving MHD.

CoQ~10~ dose escalation reduced plasma concentrations of isofurans but not F~2~-isoprostanes or HDL apoA-1 Met oxidation. To our knowledge, this is the first in vivo study in any patient population to demonstrate that plasma concentrations of isofurans are modifiable by any therapeutic antioxidant strategy. Our results are consistent with previously published unrelated studies, that show that plasma F~2~-isoprostane concentrations are significantly increased in patients undergoing maintenance HD compared with healthy subjects (published healthy controls: 37.6 pg/mL \[[@CR14]\], subjects at baseline in this study: 65 pg/mL, after 1800 mg CoQ10: 72 pg/mL). In contrast, our subjects who also had elevated concentrations of isofurans at baseline (0.145 ng/mL) compared with healthy subjects (0.071 ng/mL) \[[@CR22]\] demonstrated near-normalization after maximal supplementation (0.078 ng/mL). The generation of isofurans and F~2~-isoprostanes is regulated by the availability of oxygen; in cellular environments with relatively low oxygen availability, F~2~-isoprostanes are generated from ROS, while isofurans are preferentially generated in environments with relatively high oxygen availability. *In vivo*, isofuran generation is observed during inhalation of high concentrations of oxygen in healthy subjects and in tissues with low consumption of oxygen such as the substantia nigra of Parkinson's patients \[[@CR11]\]. Mitochondrial dysfunction observed in Parkinsonism or ESRD, may lead to high cellular oxygen tension since dysfunctional mitochondria consume little oxygen. In this environment ROS formation preferentially increases the generation of isofurans but not F~2~-isoprostanes. CoQ~10~ transfers electrons from complexes 1 and 2 to complex 3 in the mitochondrial electron transport chain. The suppression of isofuran generation observed with CoQ~10~ dose escalation is consistent with the idea that CoQ~10~ improves mitochondrial function in MHD patients and reduces the generation of ROS.

In order to differentiate the effects of CoQ~10~ on mitochondrial coupling versus direct antioxidant effect, we evaluated the effect of CoQ~10~ supplementation on ApoA-1 Met oxidation, which is selective for inflammation-mediated oxidative damage by myeloperoxidase (MPO). The lack of effect of CoQ~10~ escalation on apoA-1 Met oxidation in circulating HDL suggests the salutary effect of CoQ~10~ may be due to improved local mitochondrial function rather than a systemic anti-oxidant effect. The reduction of HDL-associated lipid hydroperoxides to the corresponding lipid hydroxides is responsible for specific oxidized Met residues (Met(O) 86 and Met(O) 112) in apoA-I, the major HDL protein \[[@CR17]\]. In addition, hydrogen peroxide and hypochlorous acid (HOCl), a strong oxidant produced by the phagocyte heme enzyme myeloperoxidase may selectively oxidize Met112 and Met148 in apoA-I \[[@CR23], [@CR24]\]. In addition to the lack of effect of CoQ10 supplementation on ApoA-1 Met oxidation, no significant change in IL-6, a pro-inflammatory cytokine (11.2 ± 8.1 pg/mL at baseline; 15.7 ± 18.9 pg/mL at study conclusion (*p* = 0.56), in comparison to unrelated healthy controls with a median IL-6 concentration: 3.8 pg/mL) \[[@CR25]\], was observed during this study, providing more presumptive evidence that the actions of CoQ~10~ are not due to a global anti- inflammatory effect. Taken together, our observations support the hypothesis that CoQ~10~ supplementation reduces mitochondrial oxidative stress, rather than by increasing general antioxidant or anti-inflammatory capacity. However, we cannot rule out some contribution of general antioxidant effect to the observed reduction in oxidative stress markers.

This study has several limitations that are inherent to fixed-sequence dose escalation studies. The dosing design does not allow us to fully attribute the observed effect on markers of oxidative stress to escalated dose or duration of CoQ~10~ supplementation and were unable to control for the effects of disease progression during the study. This study was conducted in patients undergoing thrice weekly hemodialysis, and did not include patients receiving alternate methods of dialysis, including peritoneal dialysis or daily dialysis. Since the exposures to uremic toxins in patients receiving other types of dialysis or dialytic regimens differ from our study population, we are unable to generalize our findings to these other dialysis regimens. The study examined relatively short-term effects of CoQ~10~ administration. Longer term CoQ~10~ supplementation could have some safety concerns, as CoQ~10~ could precipitate drug-drug interactions---in animal studies, CoQ~10~ supplementation has been shown to affect metabolism of theophylline \[[@CR26]\], and *in vitro*, affect transport by P-glycoprotein, an intestinal drug transporter \[[@CR27]\]. CoQ~10~ supplementation could also alter the oral bioavailability of digoxin and verapamil, both P-glycoprotein substrates.

In summary, CoQ~10~ appears to be safe and well tolerated in subjects receiving MHD and may reduce oxidative stress by improving mitochondrial function. Further studies are needed to investigate the potential metabolic and clinical benefits associated with longer term CoQ~10~ supplementation.

Conclusions {#Sec15}
===========

Coenzyme Q~10~ supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, and decreases superoxide production in endothelial cells. CoQ~10~ may be especially beneficial in patients undergoing chronic hemodialysis, a population subject to increased oxidative stress. This is the first in vivo study in any patient population to demonstrate that plasma concentrations of isofurans are modifiable by any therapeutic antioxidant strategy and suggests that CoQ~10~ may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis.
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